📈 Stocks
📊 Neutral
🌍 United States
Medtronic Q1 Revenue Hits $9.8 Billion, Surpassing Fiscal 2027 Expectations
Medtronic exceeded Q1 expectations with 13.7% organic growth, bolstered by strong demand in its core cardiac and surgical businesses and strategic expansion in robotics.
Impact
10/10
💡 Key Takeaways
- Cardiac Ablation Solutions revenue surged 88% worldwide, surpassing the $2 billion trailing 12-month revenue milestone.
- The company announced a strategic investment and distribution agreement for the Cornerstone Sentire Surgical System to expand its international robotics footprint.
- Cardiac Rhythm Management delivered 15% global growth, supported by strong adoption of Micra and EV-ICD technologies.
📋 Executive Summary
Medtronic reported a strong start to fiscal 2027, posting $9.8 billion in revenue and $1.45 in adjusted EPS. The company saw 13.7% organic growth, driven by robust performance in its Cardiac Rhythm Management, Cranial & Spinal Technologies, and Surgical portfolios.
📊 Sentiment Analysis
Sentiment
📊 Neutral
Impact Score
10/10
Region
🌍 United States
Asset Class
📈 Stocks
❓ Frequently Asked Questions
Growth was driven by strong performance in the Cardiac Rhythm Management, Cranial & Spinal Technologies, and Surgical units, alongside an 88% surge in Cardiac Ablation Solutions.
📰 Source
📅 Originally published:
⚠️ Disclaimer: This content is for training purposes only and should not be considered financial advice. Always conduct your own research before making investment decisions.